Analysts expect Illumina, Inc. (NASDAQ:ILMN) to post sales of $642.50 million for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Illumina’s earnings. The lowest sales estimate is $639.36 million and the highest is $647.00 million. Illumina posted sales of $600.12 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.1%. The firm is expected to issue its next quarterly earnings results after the market closes on Tuesday, August 1st.
According to Zacks, analysts expect that Illumina will report full year sales of $642.50 million for the current year, with estimates ranging from $2.61 billion to $2.67 billion. For the next financial year, analysts expect that the company will post sales of $3.01 billion per share, with estimates ranging from $2.87 billion to $3.13 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Illumina.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.64. The business had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.71 EPS.
A number of research firms have recently issued reports on ILMN. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price target on the stock in a research note on Tuesday, April 4th. Leerink Swann restated a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective for the company in a report on Tuesday, April 4th. Morgan Stanley restated an “underweight” rating and issued a $115.00 price objective (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. Finally, BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $165.37.
In related news, EVP Omead Ostadan sold 1,672 shares of the company’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $172.73, for a total value of $288,804.56. Following the completion of the sale, the executive vice president now owns 26,242 shares in the company, valued at approximately $4,532,780.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $170.85, for a total transaction of $341,700.00. Following the completion of the sale, the executive vice president now owns 41,341 shares of the company’s stock, valued at approximately $7,063,109.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,248 shares of company stock valued at $19,373,003. 1.60% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its stake in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares during the period. Vanguard Group Inc. increased its position in shares of Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares during the last quarter. Baird Financial Group Inc. increased its position in shares of Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock worth $47,629,000 after buying an additional 256,061 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in shares of Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock worth $65,577,000 after buying an additional 145,231 shares during the last quarter. Hedge funds and other institutional investors own 93.76% of the company’s stock.
Shares of Illumina (ILMN) traded down 0.39% during trading on Wednesday, reaching $172.33. 1,246,572 shares of the company’s stock were exchanged. The stock has a market cap of $25.16 billion, a P/E ratio of 34.88 and a beta of 0.84. The company has a 50 day moving average of $177.31 and a 200 day moving average of $165.72. Illumina has a 12-month low of $119.37 and a 12-month high of $189.48.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.